Ophthalmic Drug R&D Platform

Ophthalmic diseases are niche drug discovery areas. A more knowledgeable and experienced R&D team in the relevant domains is needed for ophthalmic medication development because it is based on an understanding of ocular illnesses and changes in target tissue-specific expression. Alfa Chemistry has developed a one-stop drug design and synthesis, pharmacodynamic, pharmacokinetic, toxicology, drug trial, and preclinical ophthalmic research platform for our customers, with a focus on the pharmacodynamic, pharmacokinetic, and safety evaluation of drugs for ophthalmic diseases. For customers with needs related to the development of ophthalmic drugs, our research platform offers high-quality and effective experimental research services, expert registration application support, and project management services. It also incorporates cutting-edge drug delivery technologies and analytical methods. Our Ophthalmic Drug R&D PlatformrnAlfa Chemistry’s integrated ophthalmic research platform has built an extensive range of ophthalmic disease pharmacodynamic models and is led by medical experts with years of clinical ophthalmology experience to perform high-quality drug delivery and analytical evaluation studies in a variety of ophthalmic specialties, providing customers with a stable and high-quality non-clinical ophthalmic one-stop service. rnAdvanced Ophthalmic Drug Delivery TechnologyrnOur platform is equipped with advanced ophthalmic surgical microscopes. In addition to conventional ophthalmic ointment dosing, we can achieve uniqueness for animal species such as rabbits, dogs, minipigs, and non-human primates. Available routes of drug delivery include: Microscopic subretinal injection.rnSuprachoroidal choroidal injection.rnIntravitreal injection.rnComplete Ophthalmic Examination and Diagnostic CapabilitiesrnThe key to the preclinical evaluation of ophthalmic drugs lies in the fine manipulation and testing of the eyes of experimental animals with appropriate instruments. Alfa Chemistry has many years of practical experience and advanced equipment to solve various complex problems in ophthalmic research and provide stable, high-quality research services to our customers. We have the Spectralis HRA + OCT ophthalmic imaging platform with the latest scalable modular design. We can use this system to help our clients complete fundus fluorescein angiography and optical coherence tomography. Specific tests that can be completed are as follows: Infrared for general fundus imaging.rnRadiofrequency for general fundus imaging.rnFluorescein angiography (FA).rnOptical coherence tomography (OCT).rnIn addition, AlphaChem’s comprehensive ophthalmic testing systems include slit lamps with digital camera systems, ophthalmometers, fundus lasers, indirect fundoscopic, and ophthalmic surgical microscopes. rnFig.1 Principles for animal dry eye modeling. (Zhu J, et al. 2022) Extensive Animal Models for Ophthalmic DiseasesrnAlfa Chemistry has the ability to assist customers in establishing animal models for a wide range of ophthalmic diseases, including: Conjunctival tissue proliferation.rnDiabetic retinopathy (DR).rnRetinal neovascularization.rnAnophthalmia.rnCorneal neovascularization.rnAcute ocular inflammation model.rnChoroidal neovascularization (CNV) and subretinal fibrosis.rnReference Zhu J, et al. (2022). “Application of Animal Models in Interpreting Dry Eye Disease.” Sec. Ophthalmology. 9: 830592.